Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells $308,864.16 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.01, for a total transaction of $1,042,842.87.
• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total value of $359,058.79.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $36.59 on Friday. The firm’s 50-day moving average is $41.07 and its two-hundred day moving average is $33.61. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45. The company has a market capitalization of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of research analyst reports. Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Guggenheim lifted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. increased their target price on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Oppenheimer reissued an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, Morgan Stanley upped their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of DYN. Nisa Investment Advisors LLC increased its position in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Amalgamated Bank raised its stake in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new position in shares of Dyne Therapeutics during the 2nd quarter worth approximately $203,000. Finally, Farallon Capital Management LLC acquired a new stake in Dyne Therapeutics in the 2nd quarter valued at approximately $212,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.